Tag: ALLO

Stock Earnings

Buying Buzz: Allogene Therapeutics Inc [ALLO] CHIEF FINANCIAL OFFICER Parker Geoffrey M. acquires 190 shares of the company

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or

Insiders Updates

Taking a look at what insiders are doing to gauge the Allogene Therapeutics Inc (ALLO)’s direction

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its

Analysts Viewpoint

Negative sentiment towards ALLO reflected by a jump of 15.5% in short interest

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Allogene Therapeutics

Featured

Allogene Therapeutics, Inc. (ALLO) Stock Dipping in Aftermarket, Here’s Why

Allogene Therapeutics, Inc. (ALLO), a clinical-stage immuno-oncology company, has dipped 32.73% and hence, ALLO stock was trading at $16.40 when